Regenerative Therapies for Neurological Disorders
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SanBio is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, diseases of the eye, and Parkinson's disease.
SanBio is a scientific leader in cell therapies for regenerative medicine. Clinical testing for SanBio's products is underway.
Gary Steinberg, MD, PhD, Professor, Chair, Stanford University School of Medicine – Neurosurgery (Principal Investigator for SanBio SB623 stroke clinical trial)
Pittsburgh (CBS2 KDKA): Researchers Testing Stem Cells as Treatment for Stroke Recovery
May 16, 2016
SanBio Granted Key Patent in Treatment for Macular Degeneration
April 6, 2016
Clinical trial involving regenerative cell treatment for patients with traumatic brain injury permitted in Japan
April 1, 2016
SanBio Names Jay Stout New Manufacturing SVP
March 10, 2016
University Hospitals Case Medical Center Randomizes the First Patient in ACTIsSIMA Trial for Chronic Stroke
Dec 21, 2015
SanBio and Sunovion begin Patient Recruitment for Phase 2b Trial to Test Regenerative Treatment for Chronic Stroke in North America
October 5, 2015
SanBio Inc. begins recruiting patients to test regenerative treatment for Traumatic Brain Injury.
May 19, 2015
Sanbio Announces Publication In Stem Cells and Development.
231 S. Whisman Road
Mountain View, CA 94041-1522
info at san-bio dot com
Site Design: Formative